Epithelioid sarcoma is a rare, malignant, slow-growing type of soft-tissue cancer. It begins as a slow growing, firm lump in the deep soft tissue or skin of arms, hands and fingers. It also occurs in legs, neck, and head. The lumps are usually painless, but sometimes this sarcoma appears as ulcers which don’t even heal. It tends to have a high recurrence rate.
DelveInsight’s “Epithelioid Sarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Epithelioid Sarcoma, historical and forecasted epidemiology as well as the Epithelioid Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of Epithelioid Sarcoma Market are:
- Epithelioid sarcoma is a mesenchymal soft tissue sarcoma often arising in the extremities, usually in young adults with a pick of incidence at 35 years of age.
- The Epithelioid sarcoma incidence rate is 0.03/100,000 in the European Union and 0.05/10,000 in the USA as per RARECAREnet and the SEER18 cancer registries.
- Epithelioid sarcomas are rare, representing less than 1% of soft tissue sarcomas, and have a predilection for men (up to 2:1 male to female ratio). Most reported tumors occur in young males ranging in age from 10 to 45 years. The extremes of ages include ages 4 to 90, with a median age of 27 years.
Request for Sample Report: https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market
Scope of Epithelioid Sarcoma Market Report:
- The report covers the descriptive overview of Epithelioid Sarcoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Epithelioid Sarcoma epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Epithelioid Sarcoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Epithelioid Sarcoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epithelioid Sarcoma market
Some of Epithelioid Sarcoma Companies in Market are:
- Epizyme, Inc.
- Analysis Group, In
- WEP Clinical
- Amgen
- Merck Sharp & Dohme Corp.
- And Others
Request for Sample Report: https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market
Epithelioid Sarcoma Drugs are:
- Tazemetostat
- Doxorubicin
- Talimogene Laherparepvec
- And Many Others
Table of Contents:
- Key Insights
- Executive Summary of Epithelioid sarcoma
- Competitive Intelligence Analysis for Epithelioid sarcoma
- Epithelioid sarcoma: Market Overview at a Glance
- Epithelioid sarcoma: Disease Background and Overview
- Patient Journey
- Epithelioid sarcoma Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Epithelioid sarcoma Unmet Needs
- Key Endpoints of Epithelioid sarcoma Treatment
- Epithelioid sarcoma Marketed Products
List to be continued in report
- Epithelioid sarcoma Emerging Therapies
List to be continued in report
- Epithelioid sarcoma: Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Epithelioid sarcoma
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market